Injectable and Implantable Outpatient Drugs

Policy
Harvard Pilgrim reimburses contracted providers for the provision of covered injectable and implantable non-self-administered drugs in an outpatient setting.

Policy Definition
Injectable and Implantable Drugs must be reasonable and necessary for the diagnosis or treatment of the condition for which they are administered. Policy is in accordance with, but not limited to FDA-approved labeling, accepted compendia, manufacturer's prescribing information and/or evidence-based practice guidelines.

Prerequisite(s)
Applicable Harvard Pilgrim referral, notification and authorization policies and procedures apply. Refer to Referral, Notification and Authorization for more information.

HMO/POS/PPO
A referral is required for specialist services for HMO and in-network POS members.

Open Access HMO and POS
For Open Access HMO and Open Access POS products, no referral is required to see a contracted specialist.

Harvard Pilgrim Reimburses

HMO/POS/PPO
- The provision of injectable and implantable non-self-administered drugs that must be administered by the provider.
- Injectable/implantable medications may not be dispensed at retail/mail pharmacies, except those noted below. (Refer to list of “Pharmacy Prescription Exceptions” below.)
- Listed and unlisted drugs at a rate that will not exceed Harvard Pilgrim’s drug fee schedule allowables. Harvard Pilgrim’s drug fee schedule is periodically updated based on Average Sale Price (ASP), Average Wholesale Price [AWP], Harvard Pilgrim Specialty Pharmacy Program, or Medicare.
- FDA-approved drugs only.
- Drugs related to contraception, if the member has the birth control rider.

Pharmacy Prescription Exceptions
The non-self-administered medications listed below may be obtained at participating retail pharmacies, for members 19+. Other age restrictions may apply.

- Adacel TDAP
- Afluria
- Bexsero
- Boostrix TDAP
- Depo-Provera 400mg
- Depo-SQ Provera 104mg
- Dexamethasone injection
- Engerix-B
- Fluad
- Flublok
- Flucelvax
- Flulaval
- Fluzone
- Gardasil 9
- Havrix
- Heplisav
- Hyprerab
- Imogam
- Imovax
- Kedrab
- Kinrix
- Medroxyprogesterone 150mg
- Menactra
- Menquadfi
- Methotrexate Injection
- M-M-R II Vaccine
- Menevo
- Naloxone injection
- Pneumovax 23
- Prevnar 13
- Proquad
- Quadracel DTAP-IPV
- Recombivax HB
- Shingrix
- TDvax
- Tenivac
- Trumenba
- Twinrix
- Vaqta
- Varivax Vaccine
- Vivitrol
- Zostavax
Harvard Pilgrim Does Not Reimburse

HMO/POS/PPO

- Anabolic steroids when used for performance enhancement.
- Drug/Biotologics billed without a valid NDC number
- Drug/Biologics when the NDC number does not match to the billed revenue, HCPCS or CPT code
- Drug/Biologics when the unlisted J code does not match to the billed NDC number
- Drugs and vaccines supplied by pharmacy prescription (Refer to pharmacy prescription exceptions.)
- Drugs related to the treatment of a non-covered service
- Experimental use of botulinum toxin A and botulinum toxin Type B will not be approved
- CPT 27412 (autologous chondrocyte implantation, knee) and HCPCS code J7330 (autologous cultured chondrocytes, implant) has not also been billed for the same date of service by any provider effective on or after date of service 08/01/2020
- CPT 58300 (Insertion of intrauterine device [IUD] or any intrauterine device has not also been billed for the same date of service by any provider effective on or after date of service 08/01/2020
- CPT J7307 (Etonogestrel implant system) when billed and the associate drug delivery insertion code (CPT 11981 or 11983) has not also been billed for the same date of service by any provider effective on or after date of service 08/01/2020

Member Cost-Sharing

Services subject to applicable member out-of-pocket cost (e.g., co-payment, coinsurance, deductible).

Provider Billing Guidelines and Documentation

Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0585</td>
<td>Onabotulinumtoxin–A (Botox)</td>
<td>Experimental use of Onabotulinumtoxin–A, Rimabotulinumtoxin–B, Abobotulinumtoxin–A and Incobotulinumtoxin–A will not be approved.</td>
</tr>
<tr>
<td>J0586</td>
<td>Abobotulinumtoxin–A (Dysport)</td>
<td></td>
</tr>
<tr>
<td>J0587</td>
<td>Rimabotulinumtoxin–B (Myobloc)</td>
<td></td>
</tr>
<tr>
<td>J0588</td>
<td>Incobotulinumtoxin–A (Xeomin)</td>
<td></td>
</tr>
</tbody>
</table>

Other Information

Effective date of service 01/01/2020 Harvard Pilgrim Healthcare requires that a valid National Drug Code (NDC) number for all professional claims and all facility claims, except inpatient facility claims.

The NDC is a universal number that identifies a drug. The NDC number consists of 11 digits in a 5-4-2 format. The first five digits identify the manufacturer of the drug and are assigned by the Food and Drug Administration. The remaining digits are assigned by the manufacturer and identify the specific product and package size.

Some packages will display fewer than 11 digits, but leading zeroes can be assumed and need to be used when billing. For example:

Illustration with numbers

<table>
<thead>
<tr>
<th>Package NDC / Adding Zero / Billed NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1234-5678-91 = 01234-5678-91 =&gt; bill without dashes as 01234567891</td>
</tr>
<tr>
<td>12345-678-91 = 12345-0678-91 =&gt; bill without dashes as 12345067891</td>
</tr>
<tr>
<td>12345-6789-1 = 12345-6789-01 =&gt; bill without dashes as 12345678901</td>
</tr>
</tbody>
</table>

- Use the appropriate Level II HCPCS (J) billing code(s). Bill with a count when appropriate.
- For multiple dates of service report a separate line for each date of service with the applicable procedure code(s) and the number of units.

(continued)
• Bill vaccines using the appropriate CPT 90000 series code representing the vaccine supplied.

**Unlisted Drugs**

Bill unlisted codes as follows:

**Electronic Claim Submitters**

837P — Report the unlisted J code in the SV101-2, loop 2400 and the NDC Number with N4 qualifier in the LIN segment, loop 2410. When reporting NDC the CTP segment is required — both CTP04 (NDC count) and CTP05 (unit of measure).

837I — Report the unlisted J code in the SV202-2, loop 2400 and the NDC Number with N4 qualifier in the LIN segment, loop 2410. When reporting NDC in LIN segment the CTP segment is required — both CTP04 (NDC count) and CTP05 (unit of measure).

**Paper Claim Submitters**

CMS-1500 form: Report the unlisted J code in 24D and units in 24G. To report NDC: In shade area of the line-item field (24A-24G), enter the N4 qualifier immediately followed by 11-digit NDC number — left justified, enter 1 space then qualifier for dispensing unit of measure followed by quantity.

UB-04 form: Report the unlisted J code in Form Locator 44 and units in Form Locator 46. To report NDC: In Form Locator 43 enter the N4 qualifier immediately followed by 11-digit NDC number without hyphens — left justified. NDC will be followed immediately by the qualifier for dispensing unit of measure followed by quantity.

**Related Policies**

- **Billing Requirements for Outpatient Revenue Codes**
- **Botox Medical Review Criteria**
- **Claims Submission Guidelines**
- **Drug Wastage Payment Policy**
- **Gynecology Payment Policy**
- **Home Infusion Therapy Payment Policy**
- **Oncology and Chemotherapy Payment Policy**
- **Prescription Drug Management Program**
- **Prior Authorization Policy**
- **Vaccine and Immunization Payment Policy**

**PUBLICATION HISTORY**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/01</td>
<td>original documentation</td>
</tr>
<tr>
<td>08/01/03</td>
<td>effective 08/01/03 listed and unlisted drug reimbursement not to exceed Harvard Pilgrim drug fee schedule or Specialty Pharmacy Program rates; added billing unlisted J codes</td>
</tr>
<tr>
<td>04/30/04</td>
<td>authorization and reimbursement sections modified</td>
</tr>
<tr>
<td>01/31/06</td>
<td>annual review and coding update; listed Botox covered diags</td>
</tr>
<tr>
<td>01/31/07</td>
<td>annual review and coding update; additional covered diags for Myobloc; Gardasil and Dexamethasone injection as pharm script exceptions; NDC for UB billing of unlisted J codes</td>
</tr>
<tr>
<td>01/31/08</td>
<td>annual review; edited Botox covered diags; minor edits</td>
</tr>
<tr>
<td>10/31/08</td>
<td>added experimental use of botulinum toxin A and botulinum toxin Type B will not be approved</td>
</tr>
<tr>
<td>01/31/09</td>
<td>annual review and coding update; edited Botox covered diags, clarified paper UB-40 claim submission, added ASP reference</td>
</tr>
<tr>
<td>05/15/09</td>
<td>clarification of covered Botox diags</td>
</tr>
<tr>
<td>11/15/09</td>
<td>annual review; no changes</td>
</tr>
<tr>
<td>01/15/10</td>
<td>annual coding update; edited botox description</td>
</tr>
<tr>
<td>03/15/10</td>
<td>added Cervarix to pharmacy prescription exceptions</td>
</tr>
<tr>
<td>11/15/10</td>
<td>annual review; no changes</td>
</tr>
<tr>
<td>01/01/12</td>
<td>removed First Seniority Freedom information from header</td>
</tr>
<tr>
<td>01/15/12</td>
<td>annual coding review; removed covered dx's from botox codes and added new botox code</td>
</tr>
<tr>
<td>11/15/12</td>
<td>annual review; minor edits</td>
</tr>
<tr>
<td>11/15/13</td>
<td>annual review; administrative edits</td>
</tr>
<tr>
<td>08/15/14</td>
<td>added Connecticut Open Access HMO referral information to Prerequisites</td>
</tr>
<tr>
<td>11/15/14</td>
<td>annual review; no changes</td>
</tr>
<tr>
<td>11/15/15</td>
<td>annual review; added Naloxone to pharmacy exceptions, updated billing for unlisted drugs, added NDC information</td>
</tr>
<tr>
<td>02/15/16</td>
<td>added Botulinum A and B toxin Medical Policy as a related policy</td>
</tr>
<tr>
<td>11/15/16</td>
<td>annual review; removed drugs from pharmacy exceptions and Botox</td>
</tr>
<tr>
<td>11/15/17</td>
<td>annual review; no changes</td>
</tr>
<tr>
<td>01/01/18</td>
<td>added report multiple dates of service on a separate line; updated Open Access Product referral information under Prerequisites</td>
</tr>
<tr>
<td>11/01/18</td>
<td>annual review; updated pharmacy exceptions list; updated related policies; administrative edits</td>
</tr>
<tr>
<td>04/01/19</td>
<td>update to pharmacy exceptions</td>
</tr>
<tr>
<td>11/01/19</td>
<td>annual review; updated Harvard Pilgrim Does Not Reimburse, added NDC required effective 01/01/20 to Other Information; added Drug Wasted Payment Policy to Related Policies</td>
</tr>
<tr>
<td>06/01/20</td>
<td>edited Policy Definition, added HPHC does not reimburse certain codes when the associated code(s) has not been billed</td>
</tr>
<tr>
<td>11/02/20</td>
<td>annual review; administrative edits; updated pharmacy exception list</td>
</tr>
</tbody>
</table>
This policy applies to the products of Harvard Pilgrim Health Care and its affiliates—Harvard Pilgrim Health Care of Connecticut, Harvard Pilgrim Health Care of New England, and HPHC Insurance Company—for services performed by contracted providers. Payment is based on member benefits and eligibility, medical necessity review, where applicable, and provider contractual agreement. Payment for covered services rendered by contracted providers will be reimbursed at the lesser of charges or the contracted rate. (Does not apply to inpatient per diem, DRG, or case rates.) HPHC reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated annually. Always use the most recent CPT and HCPCS coding guidelines.

This list is subject to change.

The table may not include all provider claim codes related to injectable and implantable outpatient drugs.